Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR‐overexpressing breast cancer cell lines (MCF7/ADR, MDA‐MB‐231)

Some kinds of breast cancer cell lines, similar to several types of solid tumors, express epidermal growth factor receptor (EGFR). However, gefitinib, an EGFR tyrosine kinase inhibitor, is not effective for all these cell lines. Similarly, taxane is effective for many of the cell lines, although some, such as the multidrug‐resistant MCF7/ADR cell line, show taxane‐resistance. Here, we examined the growth inhibitory effect of combination treatment with gefitinib and taxane on the breast cancer cell lines MDA‐MB‐231 (EGFR‐positive) and MCF7/ADR (EGFR‐ and HER2‐positive). To estimate the combined effect, a Combination Index was calculated for each cell line. The combination of gefitinib and taxane showed a strong synergistic effect on MCF7/ADR cells, but an invitro additive‐antagonistic effect on MDA‐MB‐231 cells. Similarly, the combination treatment showed a significantly increased tumor inhibitory effect on MCF7/ADR xenografts, but not on MDA‐MB‐231 xenografts. Regarding the mechanism of the synergistic effect, Western blotting analysis revealed that taxane activated the EGFR‐Akt pathway in MCF7/ADR cells but not in MDA‐MB‐231. To determine the optimal sequential administration of gefitinib and taxane for MCF7/ADR cells, we used flow cytometry to analyze the cell cycle and apoptosis; finding that taxane treatment followed by gefitinib produced a higher rate of G2 arrest and apoptosis than gefitinib treatment followed by taxane. These results suggest gefitinib overcomes the drug‐resistance of these cells, thereby increasing the effects of taxane on MCF7/ADR cells. Further, activation of the EGFR‐Akt pathway by taxane is related to this synergistic effect. © 2006 Wiley‐Liss, Inc.

[1]  S. Kohno,et al.  Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. , 2005, Lung cancer.

[2]  A. Giordano,et al.  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. , 2005, Frontiers in bioscience : a journal and virtual library.

[3]  J. Baselga,et al.  Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Whang‐Peng,et al.  Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. , 2005, Cancer research.

[5]  J. Robertson,et al.  Overview of tyrosine kinase inhibitors in clinical breast cancer. , 2005, Endocrine-related cancer.

[6]  H. Gogas,et al.  Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group , 2005, Breast Cancer Research and Treatment.

[7]  G. Tortora,et al.  Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Kohno,et al.  Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. , 2005, Cancer research.

[9]  N. Magné,et al.  [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer]. , 2004, Bulletin du cancer.

[10]  R. Roskoski.  The ErbB/HER receptor protein-tyrosine kinases and cancer. , 2004, Biochemical and biophysical research communications.

[11]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[12]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[13]  K. Gelmon,et al.  Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction , 2004, Clinical Cancer Research.

[14]  M. Campiglio,et al.  Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level , 2004, Journal of cellular physiology.

[15]  N. Saijo,et al.  Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells , 2004, International journal of cancer.

[16]  P. Fasching,et al.  A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer , 2004, Breast Cancer Research and Treatment.

[17]  N. Magné,et al.  Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil , 2003, British Journal of Cancer.

[18]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[19]  A. Levitzki,et al.  Cisplatin-induced activation of the EGF receptor , 2002, Oncogene.

[20]  G. Zupi,et al.  ZD1839 (IRESSA), an EGFR‐selective tyrosine kinase inhibitor, enhances taxane activity in bcl‐2 overexpressing, multidrug‐resistant MCF‐7 ADR human breast cancer cells , 2002, International journal of cancer.

[21]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  R. Nicholson,et al.  Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. , 2002, Cancer research.

[23]  N. Anderson,et al.  ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression , 2001, International journal of cancer.

[24]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[25]  N. Rosen,et al.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.

[26]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  N. Holbrook,et al.  Epidermal Growth Factor Receptor-dependent Akt Activation by Oxidative Stress Enhances Cell Survival* , 2000, The Journal of Biological Chemistry.

[28]  I. Tannock,et al.  Influence of cell concentration in limiting the therapeutic benefit of P‐glycoprotein reversal agents , 1999, International journal of cancer.

[29]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.